# Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease

> **NCT02570035** · — · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 316 (actual)

## Conditions studied

- Overactive Bladder
- Cardiovascular Disease

## Interventions

- **DRUG:** Mirabegron

## Key facts

- **NCT ID:** NCT02570035
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 316 (ACTUAL)
- **Last updated:** 2015-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02570035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02570035, "Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02570035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*